StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
38
This month
2
This year
5
Publishing Date
2024 - 04 - 05
1
2024 - 04 - 01
1
2024 - 03 - 18
1
2024 - 02 - 05
1
2024 - 01 - 30
1
2023 - 12 - 06
1
2023 - 11 - 08
1
2023 - 10 - 04
1
2023 - 09 - 14
1
2023 - 08 - 08
1
2023 - 07 - 28
1
2023 - 05 - 30
1
2023 - 05 - 08
1
2023 - 01 - 19
1
2023 - 01 - 17
1
2022 - 12 - 07
1
2022 - 11 - 08
1
2022 - 10 - 06
1
2022 - 09 - 12
1
2022 - 07 - 18
1
2022 - 05 - 31
1
2022 - 04 - 11
1
2022 - 01 - 22
1
2022 - 01 - 19
1
2021 - 12 - 09
1
2021 - 11 - 11
1
2021 - 10 - 11
1
2021 - 09 - 17
1
2021 - 09 - 07
1
2021 - 08 - 04
1
2021 - 07 - 29
1
2021 - 07 - 28
1
2021 - 07 - 22
1
2021 - 07 - 02
1
2021 - 05 - 26
1
2021 - 05 - 20
1
2021 - 05 - 03
1
2021 - 03 - 10
1
Sector
Health services
38
Health technology
2
Tags
Alliances
2
Als
2
Asco
4
Biotech-bay
2
Bladder
3
Breast
6
Breast cancer
3
Cancer
38
China
2
Clinical-trials-phase-iii
2
Collaboration
3
Colorectal cancer
6
Commercialization
3
Conference
17
Covid-19
2
Dating
3
Deadline
8
Diagnostic
6
Disease
6
Earnings
6
Events
14
Expected
2
Fda
3
Foundationone
2
Gastrointestinal
2
Genetic
11
Global
4
Granted
2
Growth
16
Health
9
Heart
4
Immunotherapy
3
Implant
2
In vitro
2
Kidney
12
Liberty
4
Lone-star-bio
37
Lung
3
Management
2
Market
13
Meeting
3
Melanoma
2
Milestone
2
N/a
109
Offering
5
One
2
People
5
Positive
3
Publication
10
Report
13
Research
24
Results
10
Star
4
Study
10
Symposium
5
Technology
3
Test
35
Therapy
3
Treatment
3
Trial
16
Entities
Becton, dickinson and company
1
Bio-rad laboratories, inc.
1
Biocept, inc.
2
Exact sciences corporation
1
Hologic, inc.
1
Illumina, inc.
2
Laboratory corporation of america holdings
1
Myriad genetics, inc.
1
Natera, inc.
38
Qiagen n.v.
1
Symbols
A
27
ABBV
53
ABT
49
ALPMF
50
ALPMY
50
AMGN
91
ANIX
49
ARAY
26
AVEO
24
AZN
144
AZNCF
74
BCTX
50
BDX
26
BGNE
59
BIOC
31
BMY
107
BPMC
27
CLVS
33
CSTL
28
EXAS
56
EXEL
43
FNCTF
138
GH
54
GILD
59
GLAXF
46
GNPX
26
GSK
54
GTHX
27
HOLX
32
HOTH
29
IBRX
30
ILMN
68
IMGN
25
IMMP
34
INCY
57
JAGX
37
JNJ
139
KPTI
27
LLY
139
LTRN
25
MRK
75
MRTX
32
MYGN
50
NTRA
38
NVCR
31
NVS
106
NVSEF
91
NVTA
25
ONCY
41
PDSB
35
PFE
66
QGEN
31
REGN
42
SGEN
55
SNY
217
SNYNF
167
TAK
35
TMO
51
VCYT
46
VSTM
25
Exchanges
Nasdaq
38
Nyse
3
Crawled Date
2024 - 04 - 05
1
2024 - 04 - 01
1
2024 - 03 - 18
1
2024 - 02 - 05
1
2024 - 01 - 30
1
2023 - 12 - 06
1
2023 - 11 - 08
1
2023 - 10 - 04
1
2023 - 09 - 14
1
2023 - 08 - 08
1
2023 - 07 - 28
1
2023 - 05 - 30
1
2023 - 05 - 08
1
2023 - 01 - 19
1
2023 - 01 - 17
1
2022 - 12 - 07
1
2022 - 11 - 08
1
2022 - 10 - 06
1
2022 - 09 - 12
1
2022 - 07 - 18
1
2022 - 05 - 31
1
2022 - 04 - 11
1
2022 - 01 - 22
1
2022 - 01 - 19
1
2021 - 12 - 09
1
2021 - 11 - 11
1
2021 - 10 - 11
1
2021 - 09 - 17
1
2021 - 09 - 07
1
2021 - 08 - 04
1
2021 - 07 - 29
1
2021 - 07 - 28
1
2021 - 07 - 22
1
2021 - 07 - 02
1
2021 - 05 - 26
1
2021 - 05 - 20
1
2021 - 05 - 03
1
2021 - 03 - 10
1
Crawled Time
09:00
1
12:00
2
12:30
2
13:00
4
13:15
2
13:20
2
13:30
2
14:00
4
14:20
2
14:30
2
15:00
4
15:15
1
15:20
1
16:00
3
17:00
2
17:02
1
20:20
1
21:00
2
Source
www.biospace.com
27
www.prnewswire.com
11
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Cancer
symbols :
Ntra
save search
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published:
2024-04-05
(Crawled : 12:30)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
-1.75%
|
O:
2.12%
H:
4.35%
C:
2.25%
bladder
positive
cancer
trial
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Published:
2024-04-01
(Crawled : 17:00)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
-0.46%
|
O:
-0.6%
H:
2.8%
C:
2.25%
cancer
trials
trial
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
Published:
2024-03-18
(Crawled : 12:30)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
1.7%
|
O:
0.19%
H:
1.46%
C:
0.48%
cancer
trial
New Study Validates Signatera™ in Endometrial Cancer
Published:
2024-02-05
(Crawled : 13:30)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
34.42%
|
O:
-0.89%
H:
2.74%
C:
2.52%
cancer
study
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
Published:
2024-01-30
(Crawled : 13:30)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
37.09%
|
O:
-1.07%
H:
1.73%
C:
0.46%
lung
cancer
publication
risk
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
Published:
2023-12-06
(Crawled : 14:30)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
56.21%
|
O:
1.08%
H:
0.45%
C:
-1.71%
breast
cancer
treatment
sabcs
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
Published:
2023-11-08
(Crawled : 21:00)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
108.62%
|
O:
-0.09%
H:
0.0%
C:
-5.18%
breast
cancer
treat
trial
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
Published:
2023-10-04
(Crawled : 15:00)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
107.14%
|
O:
0.68%
H:
0.24%
C:
-2.46%
lung
cancer
publication
risk
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
Published:
2023-09-14
(Crawled : 15:00)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
64.04%
|
O:
0.32%
H:
0.41%
C:
-5.51%
breast
cancer
collaboration
United States Women Health Laboratory Testing Market Analysis 2023-2028 - Cancer Prevalence Among Women Creates New Opportunities
Published:
2023-08-08
(Crawled : 16:00)
- prnewswire.com
LH
M
|
$207.94
-0.01%
0.0%
790K
|
Health Services
|
-4.83%
|
O:
-0.76%
H:
0.7%
C:
0.52%
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
78.44%
|
O:
0.69%
H:
3.99%
C:
2.63%
health
cancer
women
market
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
Published:
2023-07-28
(Crawled : 15:00)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
100.88%
|
O:
1.61%
H:
0.92%
C:
-0.37%
cancer
trial
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
Published:
2023-05-30
(Crawled : 13:00)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
87.25%
|
O:
0.12%
H:
1.17%
C:
-3.29%
asco
cancer
meeting
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
Published:
2023-05-08
(Crawled : 14:00)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
68.28%
|
O:
-0.07%
H:
0.37%
C:
-1.78%
breast
cancer
publication
trial
New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023
Published:
2023-01-19
(Crawled : 14:20)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
122.16%
|
O:
-1.54%
H:
1.59%
C:
-1.56%
symposium
gastrointestinal
asco
cancer
Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal Cancer
Published:
2023-01-17
(Crawled : 14:20)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
117.69%
|
O:
-1.05%
H:
1.4%
C:
-3.33%
cancer
publication
study
Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium
Published:
2022-12-07
(Crawled : 15:00)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
134.64%
|
O:
-1.21%
H:
1.93%
C:
0.34%
breast
symposium
cancer
Global Liquid Biopsy Market Report 2022: Increased Awareness Regarding Cancer Boosts 13.77% Annual Growth
Published:
2022-11-08
(Crawled : 21:00)
- prnewswire.com
BIO
|
$278.21
-2.48%
0.0%
210K
|
Health Technology
|
-25.29%
|
O:
-0.44%
H:
6.91%
C:
6.14%
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
114.51%
|
O:
3.06%
H:
0.43%
C:
-15.25%
MYGN
|
$18.61
0.05%
0.05%
480K
|
Health Technology
|
3.33%
|
O:
-0.78%
H:
5.43%
C:
3.08%
ILMN
|
$122.74
-1.38%
-1.4%
1.2M
|
Health Technology
|
-42.92%
|
O:
-1.08%
H:
1.4%
C:
0.07%
BIOC
|
$0.4349
-10.32%
750K
|
Health Services
|
-45.63%
|
O:
-1.24%
H:
3.8%
C:
-6.33%
global
report
cancer
growth
market
New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer
Published:
2022-10-06
(Crawled : 13:20)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
95.2%
|
O:
0.45%
H:
1.75%
C:
0.38%
test
cancer
publication
ovarian cancer
Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings
Published:
2022-09-12
(Crawled : 15:20)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
72.03%
|
O:
1.25%
H:
0.0%
C:
-0.5%
treatment
cancer
Medicare Extends Coverage of Natera's Signatera™ MRD Test to Muscle Invasive Bladder Cancer
Published:
2022-07-18
(Crawled : 16:00)
- biospace.com/
NTRA
|
News
M
|
$91.47
0.47%
0.47%
810K
|
Health Services
|
98.69%
|
O:
0.83%
H:
4.89%
C:
-5.67%
test
bladder
cancer
← Previous
1
2
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.